HHS FREEZES HIRING FOR 45 DAYS TO ASSESS EFFECTS OF GRAMM-RUDMAN-HOLLINGS balanced budget law. A departmental directive issued Feb. 13 from HHS Secretary Otis Bowen's office prohibits HHS agencies from hiring new staff and restricts HHS administrative spending. According to a memo outlining the action, the hiring freeze will give HHS Assistant Secretary for Management and Budget John O'Shaughnessy time to determine the effects of the Gramm-Rudman-Hollings balanced budget law on the department's program and administration. The law requires reductions totaling $1.03 bil. at HHS in fiscal 1986. The cuts are scheduled to take effect March 1. "While we're determining where to apply the reductions, we must maintain careful control over expenditures to retain our flexibility," the memo says. The directive freezes hiring throughout HHS on nearly all but "direct patient care employees in the Public Health Service," a department spokesman explained. Staffing at NIH's Clinical Center, for example, would be exempted from the hiring freeze. The directive also limits internal personnel movements across organizational lines within the department. The departmental action further calls for "discretionary administrative spending" throughout HHS. This limits "particularly travel, equipment purchases and rentals, contracts," and similar expenditures, the memo says. The secretary will assess the need to extend the directive after HHS reviews FY 1986 spending cuts under Gramm-Rudman-Hollings.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
The European Medicines Agency’s human medicines committee, the CHMP, has recommended 14 new medicines for pan-EU approval this month, including five orphan medicines.
The European Medicines Agency says that Eli Lilly's Alzheimer's disease drug should be approved for use in the EU, now that it has re-examined the negative opinion it previously adopted.
The European Medicines Agency recommended against pan-EU marketing authorization of Roche/Sarpeta’s gene therapy Elevidys for the treatment of Duchenne muscular dystrophy as the US reported another death in an Elevidys patient.
